Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 16, 2019 07:30 ET | Source: Biofrontera AG

Biofrontera reports further positive results from the phase III trial with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
April 16, 2019 05:30 ET | Source: Biofrontera AG

Biofrontera Announces Conference Call on April 29, 2019 to Discuss 2018 Financial Results

Leverkusen, Germany, April 16, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing...
April 15, 2019 06:15 ET | Source: Biofrontera AG

Biofrontera reports preliminary unaudited sales revenue for the first three months of 2019

Leverkusen, Germany, April 15, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reports...
April 02, 2019 08:30 ET | Source: Biofrontera AG

Biofrontera provides information on the announced voluntary public tender offer by Maruho Deutschland GmbH

Leverkusen, Germany, April 02, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...
March 27, 2019 09:05 ET | Source: Biofrontera AG

Changes in the composition of the Supervisory Board

Leverkusen, Germany, March 27, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the...
March 25, 2019 11:30 ET | Source: Biofrontera AG

Biofrontera provides corporate update; conference call details for March 26, 2019

Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces a...
March 25, 2019 10:00 ET | Source: Biofrontera AG

Biofrontera, Inc., USA, acquires Cutanea Life Sciences, Inc., USA

Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera Inc., USA (“Biofrontera”), a wholly owned subsidiary of Biofrontera AG (NASDAQ ticker...
March 20, 2019 10:50 ET | Source: Biofrontera AG

Biofrontera Reports Positive Phase III Results with Ameluz® for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 20, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical...
March 19, 2019 07:42 ET | Source: Biofrontera AG

Biofrontera AG and Maruho Co., Ltd. conclude cooperation agreement regarding branded generics and plan collaboration on expansion of indications and distribution of Ameluz®

Ad-hoc Release pursuant to Art. 17 MAR Leverkusen, Germany, March 19, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today signed an agreement to...
February 25, 2019 09:30 ET | Source: Biofrontera AG

Biofrontera Honored with Prestigious Silver Stevie(R) Award for Outstanding U.S. Customer Service Department of the Year

Leverkusen, Germany, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, today announced that...